Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
4,64 USD | +0,43% | +8,96% | -14,76% |
16/05 | SAGIMET BIOSCIENCES INC. : Goldman Sachs herhaalt koopadvies | ZM |
15/05 | Sagimet Biosciences Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024 | CI |
Vakgebied
Aantal werknemers: 9
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Therapeutics for the Treatment of Non-alcoholic Steatohepatitis and Other Diseases
100,0
%
| 0 | nan % | 2 | 100,0 % | - |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 2 | 100,0 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Happel
CEO | Chief Executive Officer | 62 | 24-10-22 |
George Kemble
CHM | Chairman | 63 | 15-08-11 |
Elizabeth Rozek
CMP | Compliance Officer | 53 | 01-04-23 |
Chief Tech/Sci/R&D Officer | - | 01-01-13 | |
Chief Tech/Sci/R&D Officer | 61 | 01-02-21 | |
Merdad Parsey
BRD | Director/Board Member | 61 | 30-09-10 |
Gaeton Biscardi
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 01-04-07 |
Richard Rodgers
BRD | Director/Board Member | 57 | 01-03-15 |
Director/Board Member | 60 | 01-04-21 | |
David Happel
CEO | Chief Executive Officer | 62 | 24-10-22 |
Jinzi Wu
BRD | Director/Board Member | 61 | 01-02-19 |
George Kemble
CHM | Chairman | 63 | 15-08-11 |
Merdad Parsey
BRD | Director/Board Member | 61 | 30-09-10 |
- | - | ||
- | - | ||
- | - |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 1 520 490 | 0 | 0 | 81,64 % |
Aandeel B | 1 | 30 393 397 | 26 054 281 ( 85,72 %) | 0 |
Bedrijfsgegevens
Sagimet Biosciences, Inc.
155 Bovet Road Suite 303
94402, San Mateo
+650-561-8600
http://www.sagimet.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-14,76% | 151 mln. | |
+42,87% | 54,04 mld. | |
+43,57% | 41,96 mld. | |
-1,16% | 41,92 mld. | |
-7,59% | 28,35 mld. | |
+11,95% | 26,35 mld. | |
-22,02% | 19 mld. | |
+7,58% | 13 mld. | |
+28,86% | 12,28 mld. | |
+25,91% | 12,19 mld. |
- Beurs
- Aandelen
- Koers SGMT
- Onderneming Sagimet Biosciences Inc.